AACR logo

More articles from MCT First Disclosures

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Joanne M. Munck, Valerio Berdini, Luke Bevan, Jessica L. Brothwood, Juan Castro, Aurélie Courtin, Charlotte East, Roberta Ferraldeschi, Tom D. Heightman, Christopher J. Hindley, Justyna Kucia-Tran, John F. Lyons, Vanessa Martins, Sandra Muench, Christopher W. Murray, David Norton, Marc O'Reilly, Michael Reader, David C. Rees, Sharna J. Rich, Caroline J Richardson, Alpesh D Shah, Lukas Stanczuk, Neil T. Thompson, Nicola E. Wilsher, Alison J.-A. Woolford, Nicola G. Wallis

Molecular Cancer Therapeutics Jul 2021, DOI: 10.1158/1535-7163.MCT-20-0909
SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors
Alba Gonzalez-Junca, Frances D. Liu, Archana S. Nagaraja, Alyssa Mullenix, Chen-Ting Lee, Russell M. Gordley, Daniel O. Frimannsson, Ori Maller, Brian S. Garrison, Dharini Iyer, Anissa Benabbas, Tiffany A. Truong, Allison Quach, Mengxi Tian, Rowena Martinez, Rishi Savur, Alyssa Perry-McNamara, Denny Nguyen, Niran Almudhfar, Carmina Blanco, Christina Huynh, Asish Nand, Yu-An E. Lay, Ashita Magal, Sravani Mangalampalli, Philip J. Lee, Timothy K. Lu, Gary Lee

Molecular Cancer Therapeutics Sep 2021, 20 (9) 1508-1520; DOI: 10.1158/1535-7163.MCT-21-0030
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
Brion W. Murray, Dayong Zhai, Wei Deng, Xin Zhang, Jane Ung, Vivian Nguyen, Han Zhang, Maria Barrera, Ana Parra, Jessica Cowell, Dong J. Lee, Herve Aloysius, Evan Rogers

Molecular Cancer Therapeutics Sep 2021, 20 (9) 1499-1507; DOI: 10.1158/1535-7163.MCT-21-0221
Harnessing the hERG1/β1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers
Claudia Duranti, Jessica Iorio, Tiziano Lottini, Elena Lastraioli, Silvia Crescioli, Giacomo Bagni, Matteo Lulli, Chiara Capitani, Rayhana Bouazzi, Matteo Stefanini, Laura Carraresi, Luisa Iamele, Hugo De Jonge, Annarosa Arcangeli

Molecular Cancer Therapeutics Aug 2021, 20 (8) 1338-1349; DOI: 10.1158/1535-7163.MCT-20-1111
ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models
Roger A. Smith, David J. Zammit, Nitin K. Damle, Helen Usansky, Sanjeeva P. Reddy, Jun-Hsiang Lin, Mahesh Mistry, Niranjan S. Rao, Louis J. Denis, Sandeep Gupta

Molecular Cancer Therapeutics Aug 2021, 20 (8) 1327-1337; DOI: 10.1158/1535-7163.MCT-20-0565
F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd
Joel Morris, Donn G. Wishka, Omar D. Lopez, Vladimir Rudchenko, Guangfei Huang, Sierra N. Hoffman, Suzanne Borgel, Kyle Georgius, John Carter, Howard Stotler, Mark W. Kunkel, Jerry M. Collins, Melinda G. Hollingshead, Beverly A. Teicher

Molecular Cancer Therapeutics Apr 2021, 20 (4) 625-631; DOI: 10.1158/1535-7163.MCT-20-0738
Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer
Juniper A. Scribner, Jennifer G. Brown, Thomas Son, Michael Chiechi, Pam Li, Sharad Sharma, Hua Li, Anushka De Costa, Ying Li, Yan Chen, Ann Easton, Nicholas C. Yee-Toy, Francine Z. Chen, Sergey Gorlatov, Bhaswati Barat, Ling Huang, Christina R. Wolff, Jeff Hooley, Tim E. Hotaling, Timur Gaynutdinov, Valentina Ciccarone, James Tamura, Scott Koenig, Paul A. Moore, Ezio Bonvini, Deryk Loo

Molecular Cancer Therapeutics Nov 2020, 19 (11) 2235-2244; DOI: 10.1158/1535-7163.MCT-20-0116
MMAE Delivery Using the Bicycle Toxin Conjugate BT5528
Gavin Bennett, Amy Brown, Gemma Mudd, Philip Huxley, Katerine Van Rietschoten, Silvia Pavan, Liuhong Chen, Sophie Watcham, Johanna Lahdenranta, Nicholas Keen

Molecular Cancer Therapeutics Jul 2020, 19 (7) 1385-1394; DOI: 10.1158/1535-7163.MCT-19-1092
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian, Patrice Lee, Janelle Taylor, Robert Rosler, Peter de Vries, Daniel Watson, Andres Forero-Torres, Scott Peterson

Molecular Cancer Therapeutics Apr 2020, 19 (4) 976-987; DOI: 10.1158/1535-7163.MCT-19-0873
Editorial Molecular Cancer Therapeutics: A Central Hub for First Disclosures in Cancer
Molecular Cancer Therapeutics Apr 2020, 19 (4) 975; DOI: 10.1158/1535-7163.MCT-20-0131

Main menu

User menu

Search

More articles from MCT First Disclosures

Pages

Articles

Info for

About MCT